A phase 2, open-label study was conducted to evaluate the 16 week PFS rate for neratinib given as a continual oral 240 mg dose daily in women with ERBB2 positive advaneed breast cancer (Study 201). Single 240 mg oral doses of neratinib (3x80 mg capsules ) were to be taken once daily in the morning preferably with food. The mean Chough plasma concentrations on Day 1 of months 2 through 6 are summarized in Table 56. Ctrough measured through cycle 6 did not show any significant changes with protracted treatment.